These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

194 related articles for article (PubMed ID: 16925892)

  • 1. The cost of antiretroviral drugs and influence on prescribing policies.
    Jones R; Gazzard B
    Int J STD AIDS; 2006 Aug; 17(8):499-506. PubMed ID: 16925892
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Direct costs for the treatment of HIV-infection in a German cohort after the introduction of HAART.
    Stoll M; Claes C; Schulte E; Graf von der Schulenburg JM; Schmidt RE
    Eur J Med Res; 2002 Nov; 7(11):463-71. PubMed ID: 12568973
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Highly active antiretroviral therapy (HAART) in adults with tuberculosis: current status.
    Kwara A; Flanigan TP; Carter EJ
    Int J Tuberc Lung Dis; 2005 Mar; 9(3):248-57. PubMed ID: 15786886
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Costs and benefits of HAART for patients with HIV in a public hospital in Mexico.
    Aracena-Genao B; Navarro JO; Lamadrid-Figueroa H; Forsythe S; Trejo-Valdivia B
    AIDS; 2008 Jul; 22 Suppl 1():S141-8. PubMed ID: 18664946
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The Brazilian experiment: HIV drugs for all.
    Flaer PJ; Younis MZ
    J Health Care Finance; 2009; 36(2):90-6. PubMed ID: 20499725
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Treatment adherence improves outcomes and manages costs.
    Valenti WM
    AIDS Read; 2001 Feb; 11(2):77-80. PubMed ID: 11279875
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Drugs for antiretroviral therapy. The costs of HAART].
    Jablonowski H
    MMW Fortschr Med; 2008 Apr; 150 Spec No 1():21. PubMed ID: 19024911
    [No Abstract]   [Full Text] [Related]  

  • 8. Drug interactions between psychoactive substances and antiretroviral therapy in individuals infected with human immunodeficiency and hepatitis viruses.
    Neuman MG; Monteiro M; Rehm J
    Subst Use Misuse; 2006; 41(10-12):1395-463. PubMed ID: 17002989
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Interactions of cardiac and antiretroviral medication].
    Egger S; Drewe J
    Herz; 2005 Sep; 30(6):493-503. PubMed ID: 16170680
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cost-effectiveness analysis of antiretroviral drug treatment and HIV-1 vaccination in Thailand.
    Ono S; Kurotaki T; Nakasone T; Honda M; Boon-Long J; Sawanpanyalert P; Kimura K
    Jpn J Infect Dis; 2006 Jun; 59(3):168-73. PubMed ID: 16785697
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Antiretroviral treatment for HIV infection. Where we are and where we are going?].
    Sierra-Madero JG; Franco-San-Sebastián D
    Rev Invest Clin; 2004; 56(2):222-31. PubMed ID: 15377075
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Antiretroviral therapy based on protease inhibitors as a protective factor against liver fibrosis progression in patients with chronic hepatitis C.
    Macías J; Mira JA; López-Cortés LF; Santos I; Girón-González JA; González-Serrano M; Merino D; Hernández-Quero J; Rivero A; Merchante N; Trastoy M; Carrillo-Gómez R; Arizcorreta-Yarza A; Gómez-Mateos J; Pineda JA
    Antivir Ther; 2006; 11(7):839-46. PubMed ID: 17302246
    [TBL] [Abstract][Full Text] [Related]  

  • 13. 2007 costs and coverage of antiretrovirals under Medicare Part D for people with HIV/AIDS living in North Carolina.
    Sengupta S
    N C Med J; 2008; 69(1):6-13. PubMed ID: 18429558
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Antiretroviral therapy in HIV.
    Yu A; Berbari E; Temesgen Z
    J Med Liban; 2006; 54(2):74-9. PubMed ID: 17086997
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Costs and adherence to antiretroviral treatment].
    Ventura-Cerdá JM; Ayago-Flores D; Vicente-Escrig E; Mollá-Cantavella S; Alós-Almiñana M
    Farm Hosp; 2010; 34(6):284-92. PubMed ID: 20692861
    [TBL] [Abstract][Full Text] [Related]  

  • 16. When to start antiretroviral therapy?
    Wilkin TJ; Gulick RM
    Clin Infect Dis; 2008 Dec; 47(12):1580-6. PubMed ID: 18990069
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The oncology impact of highly active antiretroviral therapy.
    Schlichemeyer R; Chambers C; Gill MJ
    J Oncol Pharm Pract; 2007 Mar; 13(1):17-25. PubMed ID: 17621563
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Optimizing treatment outcomes in HIV-infected patients with substance abuse issues.
    Celentano DD; Lucas G
    Clin Infect Dis; 2007 Dec; 45 Suppl 4():S318-23. PubMed ID: 18190306
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cerebrovascular ischemic events in HIV-1-infected patients receiving highly active antiretroviral therapy: incidence and risk factors.
    Corral I; Quereda C; Moreno A; Pérez-Elías MJ; Dronda F; Casado JL; Muriel A; Masjuán J; Alonso-de-Leciñana M; Moreno S
    Cerebrovasc Dis; 2009; 27(6):559-63. PubMed ID: 19390181
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Expanded access to highly active antiretroviral therapy: a potentially powerful strategy to curb the growth of the HIV epidemic.
    Lima VD; Johnston K; Hogg RS; Levy AR; Harrigan PR; Anema A; Montaner JS
    J Infect Dis; 2008 Jul; 198(1):59-67. PubMed ID: 18498241
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.